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ABSTRACT: Background. As cancer progresses, methylation patterns
change to promote the tumorigenic phenotype. However, stability of
methylation markers over time and the extent that biopsy samples are
representative of larger tumor specimens are unknown. This information
is critical for clinical use of such biomarkers.
Methods. Ninety-eight patients with tumor specimens from 2 timepoints
were measured for DNA methylation in the promoter regions across 4 genes.
Results. There were no significant differences in overall methylation of
CCNA1 (cyclin A1), NDN (necdin), deleted in colorectal carcinoma (DCC),
and cluster of differentiation 1a (CD1A) within paired specimens
(p values5 .56, .17, .66, and .58, respectively). All genes showed
strong correlations between paired specimens across time. Methylation
was most consistent for CCNA1 and NDN over time.
Conclusion. This report provides the first evidence that methylation
markers measured in biopsy samples are representative of gene methyl-
ation in later specimens and suggests that biopsy markers could be rep-
resentative biomarkers for use in defining personalized treatment
utilizing epigenetic changes. VC 2015 Wiley Periodicals, Head Neck 38:
E1325–E1331, 2016
KEY WORDS: DNA methylation, head and neck cancer, stability,
time, tumor
INTRODUCTION
There is a growing body of literature showing associa-
tions between molecular markers and head and neck can-
cer. These markers are being developed as potential
clinical tools to direct treatment, identify low-risk patients
who may benefit from less harsh treatments, and predict
prognosis. The use of epigenetic markers is a promising
tool in this regard. These markers do not change the
sequence of DNA, may be reversible, and are indicative
of tumor biology.1 Specifically, variation in DNA methyl-
ation is one of the hallmark processes of cancer and,
potentially, these markers might be used as therapeutic
targets alone, or to select patients for more effective ther-
apy. For example, gene promoter hypermethylation of the
DNA repair gene, MGMT, is a prognostic marker for gli-
oma patients and is currently being evaluated as a marker
for patient selection for carmustine and temozolomide in
clinical trials.1,2 Methylation of the mismatch repair gene,
hMLH1, was found to significantly increase upon relapse
of patients with epithelial ovarian cancer and was associ-
ated with poor survival.3 Hypermethylation of a DNA
helicase gene involved in DNA replication, recombination
and DNA repair, WRN, increases sensitivity of colorectal
tumors to topoisomerase inhibitors. Combined therapy
with DNA damaging agents showed significantly better
prognosis in patients with hypermethylated WRN than in
patients with unmethylated WRN.4 Such markers offer
high translatability into the clinical setting and can allow
for personalized therapy with high efficacy depending
upon the methylation profile of a patient’s tumor.
An inherent limitation of incorporating methylation
markers clinically is that the persistence of methylation in
a tumor is unknown. As cancer progresses, methylation
patterns can change to promote the tumor phenotype.5,6
Further, methylation of specific genes could differ signifi-
cantly depending on timing and site of tumor sampling.
However, methylation markers that are known to persist
over time may potentially be used to direct treatment.
Whether biopsy specimens would be representative of
samples obtained at surgical resection is particularly
important in head and neck cancer in which nonsurgical
primary treatment is becoming more common. This report
addresses this important limitation and provides evidence
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that tumor biopsy specimens can be used to promote the
development of epigenetically based treatments for cancer
in a clinical setting. Here, we measure the methylation of
four genes across time: CCNA1 (cyclin A1), NDN (nec-
din), deleted in colorectal carcinoma (DCC), and cluster
of differentiation 1a (CD1A). A discovery-based study
previously published by our group was designed to iden-
tify novel prognostic epigenetic biomarkers for patients
with head and neck squamous cell carcinoma
(HNSCC).7,8 CCNA1 was found to be differentially meth-
ylated by human papillomavirus (HPV) status.7 NDN and
CD1A were also differentially methylated in this discov-
ery analysis, however, they were not significant, poten-
tially because of small sample size. NDN is an imprinted
gene previously implicated in epithelial ovarian, bladder,
breast, colorectal, and urothelial cancers, as well as pre-
malignant lesions, such as vulval intraepithelial neoplasia
and Barrett’s esophagus, although it has not been studied
in the context of HNSCC.7–14 CD1A was the first immune
gene found to be differentially methylated in the discov-
ery analysis. CD1A methylation has not been previously
studied in HNSCC, however, significant hypermethylation
of CD1B, CD1C, CD1DI, and CD1E has been found in
HPV-positive HNSCC tumors compared with HPV-
negative tumors.15 Deleted in colorectal carcinoma (DCC)
and CCNA1 was previously found to be hypermethylated
in HNSCC and were chosen for its role as a tumor sup-
pressor and involvement with HPV.16–20 Previous litera-
ture on the importance of these genes in HNSCC
highlights their potential clinical relevance. However, val-
idation of their methylation stability across time is critical




This study takes advantage of an established cohort of
patients with head and neck cancer from the University
of Michigan Head and Neck Cancer Specialized Program
of Research Excellence (SPORE). Details on the cohort
can be found in a separate study.21 Eligible subjects were
biopsied pretreatment and diagnosed with head and neck
squamous cell carcinoma at an outside hospital before
referral to the University of Michigan for treatment. Upon
presentation at the University of Michigan, patients may
be rebiopsied and staged during treatment planning.
Ninety-eight subjects who signed a written, informed con-
sent, had both a formalin-fixed paraffin-embedded (FFPE)
biopsy specimen from an outside hospital and a surgical
resection (n 5 70) or biopsy (n 5 28) specimen from the
University of Michigan at a second timepoint available
for microdissection and methylation analysis. Histology
was confirmed on all samples by a qualified pathologist
(J. B. M.). Areas of >70% tumor cellularity were speci-
fied for use in microdissection. Subjects completed an
epidemiological questionnaire of behavioral and patho-
physiological information. This study was approved as
being within the ethical standards of the Institutional
Review Board of the University of Michigan.
Microdissection/DNA extraction/bisulfite conversion/
human papillomavirus testing
Designated areas of FFPE tissue were microdissected
from unstained slides and DNA was extracted using the
QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA),
in accord with the manufacturer’s protocol. DNA concen-
tration was measured with a NanoDrop spectrophotometer
(Thermo Scientific, Waltham, MA). Sodium bisulfite
treatment was performed on 250 ng of DNA using the
Epitect Bisulfite Kit (Qiagen), in accord with the manu-
facturer’s recommended protocol. HPV status was deter-
mined by an ultrasensitive method using real-time
competitive polymerase chain reaction (PCR) and matrix-
assisted laser desorption/ionization mass spectroscopy, as
described and validated previously, because of its low
DNA input requirement and rapid identification of HPV
types, with high sensitivity and specificity.18,22–25
Methylation analysis
Methylation assays for promoter regions of DCC,
CD1A, and NDN, were designed using PyroMark Assay
Design 2.0 software and conducted via pyrosequencing
across 5, 2, and 3 CpG sites, respectively (Qiagen). The
promoter region of CCNA1 was sequenced across 4 CpG
sites using the Sequenom EpiTyper, a matrix-assisted
laser desorption ionization-time of flight mass
spectrometry-based platform because of its CpG-dense
promoter region and subsequent difficulty in using pyro-
sequencing methodology. These assays were designed to
cover CpG sites at or near the CpG sites found in our
previous study to be prognostic indicators of HNSCC.7
All primer sets and PCR conditions are listed in Supple-
mentary Table 1S, online only. Bisulfite single-plex PCR
amplification was performed using FastStart Taq Poly-
merase (Roche Diagnostics, Indianapolis, IN) for CCNA1,
and HotStar Taq Master Mix Kit (Qiagen) for all other
genes, with a forward and reverse primer concentration of
0.2 mM and 30 ng of bisulfite-converted DNA. Fifteen
microliters of each PCR product was combined with the
respective sequencing primer and methylation analysis by
pyrosequencing was conducted using the Pyromark MD
System (Biotage, Charlotte, NC), in accord with the man-
ufacturer’s protocol, including single-strand binding pro-
tein (PyroGold reagents). Measurement of all samples for
every methylation marker selected was not possible if
there was insufficient quantity of total extracted DNA.
Statistical analysis
Methylation values were calculated as means across all
CpG sites of each gene. Locations of each CpG site and
distance to transcription start site are listed in Supplemen-
tary Table 2S, online only. Site-specific and mean meth-
ylation from matched tissue specimens across time for
CCNA1, DCC, and CD1A were compared using a non-
parametric Wilcoxon-signed rank test because of skewed
distributions. Methylation values for NDN were compared
using a paired t test because of its Gaussian distribution.
Pearson (NDN) and Spearman (CCNA1, DCC, and CD1A)
correlation coefficients and 95% confidence intervals
(CIs) were calculated for methylation across both time-
points. The difference in methylation between timepoints
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was calculated for each gene and the differences and their
absolute values were tested for correlation with the num-
ber of days between specimens. Correlation coefficients
were also calculated subsetting by HPV status, smoking
status, days between timepoints, and specimen type of the
second sample. Differences in the amount of change in
methylation values across subsets were tested using Wald
tests from linear regression models and a correction for
false discovery was applied to the p values to adjust for
multiple comparisons of the various subgroup tests using
q values described by Storey et al.26 Multivariable analy-
ses was conducted separately for each gene using a linear
model to measure the association of days between sample
collection and methylation differences, adjusting for HPV
status, age, site, stage, and comorbidity status. Comorbid-
ity data were abstracted from the medical record and
graded by severity (none, mild, moderate, or severe) using
the Adult Comorbidity Evaluation of 27 conditions organ-
ized by 12 systems.
RESULTS
The study population consisted of 98 paired samples with
the median time between the first and second tumor tissue
specimens at 44 days (range, 8–156 days). Approximately
74% of the population was male. Tumor sites were primar-
ily distributed across the larynx, oral cavity, and orophar-
ynx (16%, 53%, and 29%, respectively) with 2% in the
hypopharynx. Most patients were HPV-negative (69%).
Only 16% were nonsmokers, whereas 46% were current
smokers, or having quit within the past 12 months, and
38% were former smokers (quit more than 1 year ago).
Mean age was 60 years (SD 5 13 years). All genes showed
a wide range of methylation levels across samples, as
expected of epigenetic markers. There were no significant
differences in overall methylation within paired specimens
of CCNA1, DCC, and CD1A, or NDN (p values 5 .56, .17,
.66, and 0.58, respectively; Table 1). The lack of significant
differences in methylation across time persisted even when
considering site-specific methylation within each gene (see
Figure 1). Patterns of methylation across CpG sites within
each gene were similar for both outside hospitals and Uni-
versity of Michigan samples, justifying the use of mean
methylation across CpG sites as an appropriate measure to
compare methylation across time.
All genes showed strong correlations between paired
specimens across time. CD1A and DCC had identical corre-
lation coefficients (rho 5 0.70; 95% CI 5 0.58–0.79 and
rho 5 0.70; 95% CI 5 0.58–0.79, respectively; Figures 2c
and 2d), whereas CCNA1 and NDN had slightly lower corre-
lations (rho 5 0.65; 95% CI 5 0.50–0.75 and rho 5 0.65;
95% CI 5 0.51–0.75, respectively; Figures 2a and 2b). There
were no correlations between the differences in methylation
between the 2 timepoints and the number of days between
specimens for any gene (CCNA1: rho 5 20.04; 95%
CI 5 20.25 to 0.17; NDN: rho 5 20.07; 95% CI 5 20.26 to
0.13; CD1A: rho 5 0.06; 95% CI 5 20.14 to 0.26; and
DCC: rho 5 20.08; 95% CI 5 20.28 to 0.12). Additionally,
there were no correlations between the absolute values of
these differences and the number of days between specimens
for any gene (CCNA1: rho 5 0.11; 95% CI 5 20.10 to 0.31;
NDN: rho 5 20.16; 95% CI 5 20.35 to 0.04; CD1A:
rho 5 20.008; 95% CI 5 20.21 to 0.19; and DCC:
rho 5 20.04; 95% CI 5 20.24 to 0.16). Multivariable mod-
els run to assess the association of days between samples and
methylation difference across time, adjusting for HPV status,
age, site, stage, and comorbidity status, also showed no sig-
nificant association between methylation differences and col-
lection times (data not shown). These results demonstrate
that methylation at both timepoints was strongly correlated
and did not differ by the number of days between specimens.
As temporal changes in methylation levels may be asso-
ciated with patient and tumor characteristics, correlations
were also calculated separately by HPV status, smoking
parameters, and whether the second specimen was from a
biopsy or surgery resection; correlations were also calcu-
lated by the length of time between specimen sampling
(Table 2). CD1A was most stable across time in HPV-
negative patients (rho 5 0.77; 95% CI 5 0.65–0.85).
Patients who had a biopsy at their second timepoint
showed the most stable methylation at NDN (rho 5 0.77;
95% CI 5 0.53–0.89), whereas patients with a surgery
resection specimen at the second timepoint showed the
most stable methylation at CD1A and DCC (rho 5 0.74;
95% CI 5 0.61–0.83 and rho 5 0.75; 95% CI 5 0.62–0.84,
respectively). Patients with shorter times between their
tumor samples (0–44 days) showed the most stable methyl-
ation at CCNA1 and CD1A (rho 5 0.71; 95% CI 5 0.52–
0.83 and rho 5 0.74; 95% CI 5 0.58–0.85, respectively).
Patients who had their second tissue sample beyond 44
days showed the most stable methylation at DCC
(rho 5 0.72; 95% CI 5 0.55–0.83). Strong correlations
across time were found for CD1A and DCC in former
smokers (rho 5 0.81; 95% CI 5 0.65–0.90 and rho 5 0.79;
95% CI 5 0.62–0.88, respectively), CCNA1 in current
TABLE 1. Percent methylation distribution for paired samples.
Gene No. of patients Initial biopsy Rebiopsy/surgery Difference* p value†
CCNA1‡ 86 23.5 (4.5–78) 24.8 (6.3–67.3) 0.9 (231.3 to 53.3) .56
CD1A‡ 94 69.2 (21.8–95.9) 69.1 (21.4–91.1) 20.2 (228.2 to 36.3) .66
DCC‡ 96 33.1 (5.7–91.2) 32.2 (3.9–85.8) 20.7 (236.9 to 43.1) .17
NDN‡ 94 42.2 (34.9–51.2) 43.0 (36.3–52.3) 0.4 (25.2 to 7.7) .58§
Abbreviations: CCNA1, cyclin A1; CD1A, cluster of differentiation 1a; DCC, deleted in colorectal carcinoma; NDN, necdin.
* Rebiopsy or surgery-initial biopsy.
† P value for paired test.
‡ Median (range).
§ Parametric test.
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smokers (rho 5 0.74; 95% CI 5 0.55–0.85), and DCC and
NDN in never smokers (rho 5 0.84; 95% CI 5 0.59–0.94
and rho 5 0.74; 95% CI 5 0.39–0.90, respectively). To
determine correlations accounting for intensity and duration
of smoking, pack-years were also considered, using 20
pack-years as a cutoff.27 Patients with <20 pack-years and
with 20 pack-years showed the most stable methylation
at CD1A (rho 5 0.78; 95% CI 5 0.57–0.89 and rho 5 0.73;
95% CI 5 0.57–0.84, respectively). None of the subset dif-
ferences we observed proved statistically significant after p
values were corrected for multiple comparisons, likely due
to sample size.
Probability of stable methylation across time
It is difficult to define methylation cutoffs that are bio-
logically relevant. To compare consistency across time, we
determined the proportion of specimens that fell within
10% and 20% of methylation at the first timepoint. Meth-
ylation was most consistent across time for CCNA1 and
NDN. Approximately 91% and 96% of patients, respec-
tively, had methylation levels of these markers at the sec-
ond time point within 20% of methylation at the first
timepoint. CD1A and DCC methylation at the second time-
point was within 20% of methylation at the first timepoint
for 85% and 79% of the patient population, respectively.
This consistency persisted when restricting methylation
change to 10%. Approximately 66% and 68% of patients
had methylation of CCNA1 and NDN at the second time-
point within 10% of methylation at the first timepoint,
respectively. The probability of CD1A and DCC methyla-
tion at the second timepoint staying within 10% of the first
timepoint was 60% and 53%, respectively.
DISCUSSION
These findings in patients with head and neck cancer
demonstrate the stability of DNA methylation changes in
tumor specimens from the time of biopsy to time of sur-
gical treatment or second biopsy ranging from 8 to 156
elapsed days. To date, this is the first study to examine
changes in methylation of specific genes across time and
from different tumor samples within the same patients.
Correlations across time and by patient characteristic
were positive and statistically significant, although the
strength of correlations differed slightly based on patient
characteristics, potentially because of underlying biologi-
cal mechanisms associated with these genes. For example,
we found that methylation of our genes was more
strongly correlated across time in HPV-negative tumors,
likely because of the fact that HPV-positive tumors tend
to have more DNA methylation events in genic regions.8
The strength of correlations was higher in specific genes
when considering patient characteristics, indicating that a
gene chosen for diagnostic purposes may depend on a
patient’s clinical profile.
FIGURE 1. Site-specific comparison of methylation at both timepoints. There are no significant differences in methylation at each CpG site for each
gene. Methylation of each gene was measured in promoter regions at (A) 4 sites for CCNA1 (cyclin A1); (B) 3 sites for NDN (necdin); (C) 5 sites for
deleted in colorectal carcinoma (DCC); and (D) 2 sites for cluster of differentiation 1a (CD1A). The location of each site, distance to transcription
start sites, and assay specifications are available in Supplementary Tables S1 and S2, online only.
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FIGURE 2. Correlations of each marker between paired specimens across time. (A) CCNA1 (cyclin A1) and (B) NDN (necdin) have similar correlation
coefficients whereas (C) cluster of differentiation 1a (CD1A) and (D) deleted in colorectal carcinoma (DCC) have similar correlation coefficients.
TABLE 2. Correlations within subsets of population.
CCNA1 CD1A DCC NDN
Parameter
No. of
patients Rho* (95% CI)
No. of
patients Rho* (95% CI)
No. of
patients Rho* (95% CI)
No. of
patients Rho* (95% CI)
Second specimen type
Biopsy 25 0.64 (0.33–0.83) 27 0.63 (0.33–0.81) 27 0.57 (0.24–0.78) 26 0.77 (0.54–0.89)
Surgery 61 0.64 (0.46–0.77) 67 0.74 (0.61–0.83) 69 0.75 (0.62–0.84) 68 0.56 (0.37–0.70)
HPV status
HPV1 27 0.52 (0.17–0.75) 29 0.45 (0.10–0.70) 29 0.49 (0.15–0.73) 28 0.57 (0.25–0.78)
HPV- 59 0.52 (0.30–0.68) 65 0.77 (0.65–0.85) 67 0.60 (0.42–0.73) 66 0.58 (0.39–0.72)
Days between specimens†
0–44 43 0.71 (0.52–0.83) 49 0.74 (0.58–0.85) 49 0.64 (0.44–0.78) 48 0.67 (0.48–0.80)
>44 43 0.52 (0.26–0.71) 45 0.68 (0.48–0.81) 47 0.72 (0.55–0.83) 46 0.65 (0.44–0.79)
Smoking status
Current 39 0.74 (0.55–0.86) 44 0.67 (0.46–0.81) 44 0.48 (0.21–0.68) 44 0.59 (0.36–0.75)
Former 33 0.58 (0.30–0.77) 34 0.81 (0.65–0.90) 36 0.79 (0.62–0.88) 34 0.68 (0.44–0.83)
Never 14 0.64 (0.17–0.87) 16 0.49 (20.01 to 0.79) 16 0.84 (0.59–0.94) 16 0.74 (0.39–0.90)
Pack-years‡
<20 26 0.65 (0.35–0.83) 27 0.78 (0.57–0.89) 28 0.67 (0.40–0.83) 28 0.59 (0.28–0.79)
20 45 0.60 (0.37–0.76) 50 0.73 (0.57–0.84) 51 0.66 (0.47–0.79) 50 0.67 (0.48–0.80)
Abbreviations: CCNA1, cyclin A1; CD1a, cluster of differentiation 1a; DCC, deleted in colorectal carcinoma; NDN, necdin; 95% CI, 95% confidence interval; HPV, human papillomavirus.
* Correlation coefficient.
† Cutoff based on median.
‡ Cutoff based on Gillison et al.17
STABILITY OF METHYLATION MARKERS
HEAD & NECK—DOI 10.1002/HED APRIL 2016 E1329
A limitation of this study was the variability of methyl-
ation within each gene. Because the differences observed
between paired specimens were uncorrelated with length
of time separating the specimens, they are instead likely
because of heterogeneity within the tumors, measurement
variability in the assay itself, measurements made across
mixed cell populations, averages taken across several
CpG sites in promoter regions, or intraindividual variabil-
ity in methylation across time. It is important to note that
although our biopsies came from a separate institution,
the management of the biopsy material is fairly standar-
dized across hospitals. The sample is placed in formalin
immediately upon excision and eventually embedded in
paraffin. There are many factors that may potentially
affect methylation, the most significant being sampling
error because of samples being taken from differing loca-
tions in the tumor (i.e., periphery for the biopsy and per-
haps more central location for the resection). However,
because minimal differences were noted in methylation
between these 2 timepoints and locations, it is unlikely
that differing institutions would be a significant variable.
In addition, our findings showed no significant differen-
ces in paired distributions, relatively strong correlation
coefficients as high as 0.84, and high probabilities of sta-
ble methylation within patients across time. These find-
ings support the conclusion that when targeting epigenetic
changes, alterations in gene methylation after initial
biopsy likely reflect biologic changes rather than sam-
pling errors. Additionally, these are issues that are likely
to impact any clinical measurement, and, thus, these
results represent a realistic assessment of the persistence
of methylation levels.
The amount of methylation change needed to instigate a
biological effect is currently unknown. Therefore, it is
important that methylation levels remain relatively consist-
ent across time when considered in a clinical setting. Here,
we show high probabilities of CCNA1 and NDN methyla-
tion to be within 10% and 20% of the first measurement.
CD1A and DCC methylation had lower probabilities indi-
cating that, in the tumor microenvironment, some genes are
stably methylated while others are not, presumably to pro-
mote the tumorigenic phenotype.
Although stability of methylation of other specific genes
could differ, our current findings are significant because these
genes have been shown to be important in HNSCC.7,8 We
report CCNA1 and DCC methylation levels similar to previous
studies.16,19,28 CD1A and NDN methylation has not been previ-
ously reported. The results of this study provide evidence for
the stability over time of specific gene methylation measured
in biopsy samples and supports the use of biopsy results as rep-
resentative of the entire tumor, and as a potential prognostic
indicator that could aid in defining personalized treatment.
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